Tanvex BioPharma, Inc. (6541.TW)
Taiwan · TWD · Healthcare · Biotechnology
NT$30.10 (-0.50%) as of
Key statistics
- Market cap
- 7.98B
- Forward P/E
- -8.05
- EPS (TTM)
- -5.56
- Dividend yield
- 0.00%
- 52-week range
- 29.60 – 65.50
- Beta
- 0.20
- Revenue (TTM)
- 657.56M
- Profit margin
- -222.84%
- Volume
- 202.60k
About Tanvex BioPharma, Inc.
Tanvex BioPharma, Inc., a pharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar products in Taiwan and the United States. The company focuses on delivering biopharmaceuticals with biosimilars targeting neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. It also engages in contract development and manufacturing of biological medicines. The company was founded in 2011 and is headquartered in George Town, the Cayman Islands.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- George Town, Cayman Islands
- Employees
- 215
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.